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Although hormone replacement therapy (HRT) is used by post-menopausal women for the
relief of menopausal symptoms and the potential reduction of osteoporosis, HRT also
increases their risk of Alzheimer’s disease, stroke, breast cancer, and endometrial cancer. Since
the majority of these effects are associated primarily with estrogen binding to only one of the
estrogen receptors (ER), new assays are needed that can more efficiently evaluate ER-binding
and identify ligands selective for ER- and ER-. High performance liquid chromatography-
tandemmass spectrometry (LC-MS-MS) was combined with ultrafiltration as a new method to
investigate the relative binding of compounds to the ERs and to evaluate the structures of these
estrogens. Mixtures of estradiol and six equine estrogens, including equilin, equilenin,
8,9-dehydroestrone, and their 17-hydroxyl derivatives, were assayed simultaneously to
determine their relative binding to human ER- and ER-. Estrogens containing a 17-OH
group were found to have higher relative affinities for the estrogen receptors than their ketone
analogs. In addition, 17-EN showed selectivity for binding to ER- over ER-. The results
were compared to the IC50 values obtained by using a conventional radiolabled estradiol
competitive binding assay. Finally, the utility of negative ion electrospray tandem mass
spectrometry for the unambiguous identification of these estrogen isomers was investigated.
Several characteristic recyclization pathways during tandem mass spectrometry were identi-
fied, which might be useful for distinguishing related estrogens. (J Am Soc Mass Spectrom
2005, 16, 271–279) © 2004 American Society for Mass SpectrometryEstrogens regulate gene expression by binding tointracellular estrogen receptors (ER- or ER-),and then to the estrogen-responsive element
(ERE) in DNA. The ER-DNA complex modulates the
transcription of estrogen-regulated target genes and
influences cell growth and differentiation [1, 2]. The two
subtypes, ER- and ER-, are different from each other
in distribution and ligand specificity [3, 4]. Most of ER-
is localized in the uterus, and small amounts are present
in ovaries, testes, skin, and gut. ER- occurs at high
levels in fetal ovaries, testes, adrenals, and spleen [5],
and both ER- and ER- are expressed in the human
central nervous system, breast, bone, and cardiovascu-
lar tissue [6]. During menopause, women often experi-
ence vasomotor symptoms (e.g., hot flashes) and other
sequelae due to low levels of estrogens [7]. Hormone
replacement therapy (HRT) may be used to reduce
these symptoms and perhaps even reduce the post-
menopausal risk of certain age-related disorders such as
osteoporosis [8, 9]. Premarin (Wyeth-Ayerst) has be-
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doi:10.1016/j.jasms.2004.11.002come the most widely prescribed HRT and contains the
equine estrogens, equilin (EQ), 8,9-dehydroestrone
(DHES), equilenin (EN), and the corresponding 17-
hydroxylated derivatives. However, long-term estrogen
replacement therapy increases the risk of developing
breast and endometrial cancer [8, 10 –12] and has been
associated with increased risks of stroke and loss of
cognitive function [13, 14].
Since many estrogen analogs that bind to human ER
are under investigation as potential new therapeutic
agents, there is a need for more efficient assays to evaluate
ER-binding and to identify ligands of ER in complex
samples such as biological matrices. Although both
LC-MS [15–20] and GC-MS [15, 16, 21–23] have been used
for the rapid and sensitive identification of estrogens and
their metabolites, GC-MS usually requires derivatization
which adds to the complexity of sample preparation,
increases the time required per analysis, and might intro-
duce artifacts. To eliminate the need for sample derivati-
zation, we developed a method based on LC-MS-MS.
From among the solution-phase ionization methods that
have been reported for the mass spectrometric analysis of
estrogens, such as fast atom bombardment (FAB) [24, 25],
atmospheric pressure chemical ionization (APCI) [15, 19],
and electrospray [15, 16, 20, 25, 26], we selected electro-
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spectrometric fragmentation pathways of estrogens have
concerned primarily estrone (E1), estradiol (E2), estriol
(E3), and 17-ethylestradiol (EE2) [15, 16, 20, 23, 26],
additional tandemmass spectrometric analyses of a wider
variety of estrogen analogs used for HRTwere carried out
in order to provide a more complete profile of estrogen
fragmentation patterns for structural characterization.
LC-MS-MS was combined with ultrafiltration to in-
vestigate the binding of ligands to estrogen receptors.
Previously in our laboratory, ultrafiltration mass spec-
trometry has been used for the screening of combina-
torial libraries and natural product extracts in order to
identify ligands for adenosine deaminase [27, 28], dihy-
drofolate reductase [29], cyclooxygenase-2 [30], and
ER- [31]. In the present study, ultrafiltration-
LC-MS-MS was used to screen a mixture of seven
estrogens in order to determine simultaneously their
relative binding to ER- and ER- under the conditions
of the assay. The estrogens included E2 and six equine
estrogens; EQ, EN, 8,9-dehydroestrone (DHES), and
their 17-hydroxyl derivatives (Figure 1). This informa-
tion is being used in our on-going studies for the
correlation of estrogen structure with binding.
Experimental
Chemicals and Reagents
All organic solvents were HPLC grade or better and were
purchased from Fisher (Hanover Park, IL). E2 was pur-
chased from Sigma (St. Louis, MO), and the other six
estrogens were synthesized by Dr. Fagen Zhang (Univer-
sity of Illinois College of Pharmacy, Chicago, IL). Human
recombinant ER- and ER- were purchased from Pan-
Figure 1. Structures of the estrogens used during this investi-
gation.vera (Madison, WI).Tandem Mass Spectrometry
Negative ion MS-MS product ion spectra were acquired
using a Micromass (Manchester, UK) Quattro II triple
quadrupole mass spectrometer equipped with electro-
spray. Nitrogen was supplied as both nebulizing and
drying gas at flow rates of 20 and 450 L/h, respectively.
The drying gas temperature was 150 °C. Argon was
used as the collision gas at a pressure of 1.1  103 bar.
The electrospray ion source was operated at 80 °C with
a capillary voltage of –2800 V and a cone voltage of 55
V. Each estrogen compound (1 M) in methanol/water
(1:1; vol/vol) containing 1% ammonia was infused into
the mass spectrometer at a flow rate of 20 L/ min. The
collision energies (between 15 and 45 eV) were opti-
mized for each compound. Abundant product ions
were selected for multiple reaction monitoring (MRM)
during the LC-MS-MS assay described below.
Binding of Estrogen Analogs to Human Estrogen
Receptors using Ultrafiltration LC-MS-MS
A mixture of estrogen analogs was incubated for 2 h at
room temperature with 100 pmol ER- or ER- in binding
buffer consisting of 50 mM Tris-HCl (pH 7.5), 10% glyc-
erol, 50 mM KCl, and 1 mM EDTA, in a total volume of
150 L. For direct comparison to the conventional estro-
gen receptor competitive binding assay based on compe-
tition of ligands with radiolabeled estradiol (see below),
the binding buffer of Liu et al. [31] was also used in one
series of experiments, which consisted of 10 mM Tris-HCl
(pH 7.5), 10% glycerol, 2 mM dithiothreitol, and 1 mg/mL
bovine serum albumin. Identical control incubations in
which ER was omitted or denatured ER was substituted
for active ER were used to correct for nonspecific binding
(adsorption) of estrogens to the ultrafiltration membrane
and holder. For the control incubations, ERwas denatured
by boiling for 10 min. After incubation each mixture was
filtered through a Microcon (Millipore, Bedford, MA)
YM-30 centrifugal filter containing a regenerated cellulose
ultrafiltration membrane with a 30,000 MW cutoff by
centrifugation at 10,000 g for 7 min at 4 °C. The filter was
washed three times by centrifugationwith 150 L aliquots
of ammonium acetate buffer (pH 7.5) at 4 °C to remove the
unbound compounds. The bound ligands were released
by adding 400 L of methanol/water (90:10; vol/vol)
followed by centrifugation at 10,000 g for 10 min. The
solvent in the ultrafiltrate was removed under vacuum,
and the released ligands were redissolved in 60 L of
methanol/water (50:50; vol/vol). Aliquots (30 L) of this
reconstituted ligand solution were analyzed using LC-
MS-MS, which consisted of a Waters (Milford, MA) 2690
HPLC system coupled to a Quattro II electrospray triple
quadrupole mass spectrometer. HPLC separations were
carried out using a Waters Xterra MS C18 (3.5 m, 2.1 
100 mm) HPLC column. The mobile phase consisted of
35% aqueous acetonitrile for 4 min at 0.2 mL/min fol-
lowed by an 11 min linear gradient from 35–50% acetoni-
trile with post-column addition of 0.1% ammonia in
273J Am Soc Mass Spectrom 2005, 16, 271–279 ULTRAFILTRATION TANDEM MS OF ESTROGENSmethanol/water (50:50, vol/vol) at 15 L/min. During
LC-MS-MS, the electrospray ion source was operated at
150 °C in negative ion mode at a cone voltage of 55 V. The
ion transitions used for MRM and the corresponding
collision energies for collision-induced dissociation (CID)
are summarized in Table 1. The dwell time was 0.20 s for
each MRM channel.
Estrogen Receptor Competitive-Binding Assays
The procedure of Obourn et al. [32] was used with
minor modifications as described by Liu et al. [31] as an
alternative measurement of estrogen binding to each
estrogen receptor. This assay measures binding to ER-
and ER- in terms of competition of ligands with
[3H]-estradiol.
Results and Discussion
Ultrafiltration LC-MS-MS Analysis of Binding to
ER- and ER-
The HPLC separation of the seven structurally similar
estrogens (Figure 1) differing primarily by a ketone or
hydroxyl group at carbon-17 or unsaturation in the B
ring was challenging. Ultimately, a 15-min separation
incorporating an 11-min slow gradient with a standard
C-18 reversed phase HPLC column was found to pro-
vide baseline separation of all seven compounds (Fig-
ure 2). In addition, the estrogens could be distinguished
using tandem mass spectrometry as discussed below.
Positive and negative ion electrospray ionization
were compared for the analysis of the estrogen analogs.
Since the deprotonated molecules of these compounds
during negative ion electrospray were more abundant
than the corresponding protonated molecules in posi-
tive ion mode, and since the fragmentation patterns of
these estrogen analogs were distinctly different in neg-
ative mode only, negative ion electrospray ionization
was used for all subsequent LC-MS-MS analyses. The
[M  H] ions of each of the seven estrogens were
selected as the precursors for CID, and the most abun-
dant fragment ions produced during CID were identi-
fied for use during MRM. The precursor and product
ion pairs for MRM and optimum CID energy for each
Table 1. Precursor/product ion pairs and collision energies
used for multiple reaction monitoring of estrogens
Compound
Precursor ion 3 Product ion
(m/z)
Collision energy
(eV)
EN 265 3 221 30
EQ 267 3 143 30
DHES 267 3 171 30
17-EN 267 3 181 30
17-EQ 269 3 267 35
17-DHES 269 3 171 30
E2 271 3 183 40estrogen analog are summarized in Table 1.Even though some compounds had the same molec-
ular weight, e.g., 17-EN, EQ, and DHES (MW 268), or
17-EQ and 17-DHES (MW 270), they produced
unique product ion mass spectra during negative ion
electrospray tandem mass spectrometry as well as elut-
ing at different retention times during HPLC. As a
result, high selectivity was obtained in the analysis of
these seven compounds during LC-MS-MS. Standard
curves for the seven estrogens were obtained using
LC-MS-MS and showed excellent linearity from 0.2–30
pmol (amount injected onto the LC-MS-MS system)
with correlation coefficients (r2) exceeding 0.996. Al-
though not needed for this application, in which the
relative binding of estrogens in a mixture was being
compared, the use of an internal standard would prob-
ably have improved the reproducibility of these assays.
Unlike our previously reported applications of ultra-
filtration mass spectrometric screening for drug discov-
ery [27–31], the present method was designed to char-
acterize the relative binding of a mixture of estrogens to
human ER- and ER-. The adsorption of ligands to the
ultrafiltration membrane and nonspecific binding to the
receptors were determined by carrying out identical
control incubations without receptor or with denatured
receptor in the solution. No differences were observed
between the controls without receptor and those with
denatured receptor. Since nonspecific binding to the
estrogen receptor was not detected, the difference in the
LC-MS-MS peak area for a ligand detected in the nativeFigure 2. LC-MS-MS of seven estrogen analogues.
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274 SUN ET AL. J Am Soc Mass Spectrom 2005, 16, 271–279ER experiment and in the corresponding control, with-
out protein or with denatured protein, corresponded to
specific binding. For example, Figure 3 shows typical
LC-MS-MS chromatograms of the estrogen mixture
acquired for the ultrafiltrates of binding experiments
with active and denatured (control) ER- and ER-.
Incubations of ER- or ER- (0.667 M) were carried
out with two different equimolar concentrations of the
seven estrogens (1 M or 0.2 M). Exemplary ultrafil-
tration mass chromatograms for these experiments are
shown in Figure 3. Based on these chromatograms and
the standard curves, enrichment factors representing
the specific binding of each estrogen to its receptor were
obtained by dividing the amount of specific binding,
which corresponds to the subfraction of the control
signal from those of the experiment, by the original
amount of each compound in the incubation solution.
All of the enrichment values are shown in Table 2 and
may be used to rank the relative binding affinities of
these estrogen analogs.
Figure 3. Ultrafiltration LC-MS-MS screening of (a) 1.0 M and
(b) 0.2 M, equimolar mixtures of the estrogens shown in Figure
1 incubated with 0.667 M ER- or ER-. The control incubations
(solid lines) containing denatured ER were used to correct for
nonspecific binding and adsorption of the sample to the ultrafil-
tration apparatus. Enhancement of HPLC peak areas in the
experimental incubations (dashed lines) indicate specific binding
of ligands to ER and were used to calculate the enhancement
factors shown in Table 2.When the concentration of each estrogen exceeded Ta E
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275J Am Soc Mass Spectrom 2005, 16, 271–279 ULTRAFILTRATION TANDEM MS OF ESTROGENSthe concentration of the receptor, only the highest
affinity estrogens showed specific binding to ER- and
ER- due to competition for receptor sites. The estro-
gens with the highest affinity for ER- and ER- were
the 17--hydroxyl compounds (17-EQ, 17-EN, 17-
DHES) and estradiol eluting between 5.5 and 8.5 min
(see Figure 3a). When estrogens at the lower concentra-
tion were incubated with excess ER, specific binding
was observed for all estrogens in the mixture but to
different extents reflecting their relative affinities for
ER- and ER- (Figure 3b and Table 2). According to
the enrichment factors shown in Table 2 (at the 0.2 M
estrogen concentration), the affinity rank order for
binding to ER- was E2  17-EQ  17 -EN 
17-DHES  DHES  EQ  EN. The rank order for
binding to ER- was slightly different with E2  17
-EN  17-EQ  17-DHES  DHES  EQ  EN.
Only 17-EN and EN showed binding selectivity to-
ward ER- compared to ER-.
Two different binding buffers were used for ultrafil-
tration LC-MS-MS, and the relative affinities of the
estrogens for ER- and ER- varied slightly depending
upon the buffer. One binding buffer contained TRIS
buffer, glycerol, KCl, and EDTA and was recommended
by the supplier of the estrogen receptors. The second
binding buffer was that used in the radiolabeled estra-
diol competition assay of Liu et al. [31] and consisted of
TRIS buffer, glycerol, dithiothreitol, and bovine serum
albumin. Since the composition of the buffer was found
to affect the relative binding of estrogens to ER- and
ER-, and since a goal of this investigation was to
validate the new ultrafiltration LC-MS-MS assay for the
rank ordering of estrogens by comparison to another
validated assay, it was necessary to use identical bind-
ing buffers for both assays. A comparison of the data
sets for both buffers indicates that the signal enhance-
ment factors obtained using ultrafiltration LC-MS-MS
and the radiolabeled estradiol competition buffer were
closest to the binding values measured using the estra-
diol competition assay (Table 2). However, the enhance-
ment factors showed the same relative order no matter
which binding buffer was used. For future assays, we
prefer to use the binding buffer recommended by the
ER supplier, since this buffer does not contain bovine
serum albumin which might compete with the ER for
some ligands.
The rank order of the binding of estrogens in an
equimolar mixture of estrogens to ER- and ER-
determined using ultrafiltration LC-MS-MS was identi-
cal to that obtained using the conventional radiolabeled
estradiol competition assay. Competitive binding with
[3H]-estradiol is a widely used method for the quanti-
tative comparison of estrogenic compounds [33]. Fur-
thermore, these data indicate that 17-EN and EN are
ER- selective, and that the 17-hydroxyl compounds
have greater affinity for human estrogen receptors than
their ketone analogs.
Since all of the compounds screened in this investi-
gation were ligands for ER- and ER-, this workshows how ultrafiltration LC-MS-MS may be used to
rapidly rank order a directed library of analogs with
respect to affinity for a specific target. Our approach is
significantly different from others in the literature such
as affinity chromatography containing immobilized re-
ceptor [34] or antibody [35] and other approaches such
as phage-display libraries [36] or ligands immobilized
on beads [37]. Unlike these other approaches, ultrafil-
tration LC-MS-MS allows the receptor and ligand to
bind in solution, which avoids potential alterations in
their pharmacological and biochemical characteristics
that might result from immobilization.
MS-MS of Estrogen Analogs
During these ultrafiltration LC-MS-MS analyses, tan-
dem mass spectrometry was used to distinguish be-
tween closely eluting estrogen analogs. This high level
of selectivity was particularly important for the unam-
biguous determination of EN and EQ which have
similar HPLC retention times of approximately 9.7 and
10.4 min, respectively (Figure 2). The CID tandem mass
spectra of [M  H] ions of all seven of the estrogens
used in this study are shown in Figure 4. During
MS-MS of these compounds, the elimination of small
neutral molecules from the [M  H] precursor ions
were commonly observed. These small molecules in-
cluded H2, CH4, and CO. The loss of H2 probably
occurred from the B ring, since this process would be
stabilized by the formation of conjugated alkenes or an
aromatic ring. The loss of CH4, CH3OH, or CO probably
occurred from the D ring and involved the 13-methyl
group and the 17-hydroxyl or carbonyl group.
The most abundant fragment ions are consistent with
the fragmentation pathway of retrocyclization. Proba-
ble sites for estrogen ring cleavage during retrocycliza-
tion are suggested in Scheme 1. In the negative ion
electrospray tandem mass spectrum of E2 (Figure 4a),
the formation of abundant product ions of m/z 183, 145,
and 143 are consistent with retrocyclization modes 1
and 3 (Scheme 1) combined with loss of H2. Fragmen-
tation pathways for the formation of these product ions
are suggested in Scheme 2. All of these product ions are
stabilized by conjugated double bonds and an aromatic
ring. Furthermore, these fragmentation pathways are
consistent with the tandem mass spectra of the other
estrogens. For example, in the tandem mass spectra of
EQ and its 17-hydroxyl derivatives, the ion of m/z 143,
but not m/z 145, was detected since there is a double
bond in the B ring for these compounds. For the same
reason, there was an ion of low abundance at m/z 183
but an abundant signal atm/z 181. Since EN and 17-EN
contain an aromatic B ring, retrocyclization mode 1
cannot occur for these compounds, and no product ions
of m/z 145 or 143 were observed. Finally, the ion m/z 239
might result from the loss of CH3OH.
The fragmentation pathways of 17-EQ are shown in
Scheme 3. The most abundant fragment ion is observed
atm/z 267 and is probably formed by the loss of H2 from
276 SUN ET AL. J Am Soc Mass Spectrom 2005, 16, 271–279Figure 4. Negative ion electrospray with CID tandem mass spectra of estrogen analogs (a) E2, (b)
EN, (c) 17-EN, (d) EQ, (e) 17-EQ, (f) DHES, and (g) 17-DHES.OH
-O
RC mode 1
RC mode 2 RC mode 4
RC mode 3
Scheme 1. Proposed recyclization modes of estrogens during
negative ion electrospray CID tandem mass spectrometry.OH
-O
-O
-O -O
-O
OH
-CH3OH
m/z 271
m/z 239
m/z 145 m/z 143
m/z 183
-H2
-
-C5H12O
Scheme 2. Proposed fragmentation pathways of the deproto-
nated molecule of E2.
277J Am Soc Mass Spectrom 2005, 16, 271–279 ULTRAFILTRATION TANDEM MS OF ESTROGENSthe B ring to give a stable aromatic ring. Similarly, the
abundant ion of m/z 265 in the tandem mass spectrum
of EQ corresponds to loss of H2. The product ions of m/z
183, 181, and 143 result from the retrocyclization modes
1 and 3 and are analogous to those of E2. Unlike E2,
17-EQ also produces ions of m/z 211, 209, 197, and 195,
which probably were formed through retrocyclization
mode 4. The ion of m/z 211 corresponds to retrocycliza-
tion mode 4 with loss of cyclopropanol (C3H6O) from
the [M  H] ion (m/z 269). The formation of m/z 197 is
consistent with loss of CH4 followed by elimination of
cyclopropanone (C3H4O). The ions of m/z 209 and 195
are probably formed from m/z 267 by retrocyclization or
fromm/z 211 and 197 by loss of H2. In addition, a radical
ion of m/z 196 can be obtained via the same pathway as
m/z 195 except that a methyl radical is eliminated
instead of methane. The fragmentation pattern of the
Scheme 4. Proposed fragmentation pathways of the deproto-
Scheme 3. Proposed fragmentation pathways of the deproto-
nated molecule of 17-EQ.nated molecule of 17-DHES.deprotonated molecule of 17-EN (Figure 4c) is similar
to that of 17-EQ and is consistent with retrocyclization
mode 4. However, the ions of m/z 145 and 143 were not
detected due to the aromatic B ring as discussed above.
The tandem mass spectrum of the deprotonated
molecule of 17-DHES (Figure 4g) shows abundant
product ions of m/z 211, 209, 197, and 195, and the
fragmentation pathway for this estrogen (Scheme 4) is
consistent with retrocyclization mode 4. However, this
pattern was quite different from 17-EQ because of the
different position of the double bond on the B ring. In
the case of 17-EQ, the 7,8-double bond is not conju-
gated with the aromatic ring, so that -H elimination is
more probable leading to loss of H2. In comparison,
17-DHES has an 8,9-double bond that is stabilized
through conjugation with the aromatic ring. Therefore,
the loss of H2 from the [MH]
 ion is unlikely, and the
fragment ion of m/z 267 is low in abundance. In addi-
tion, the position of the double bond in the B ring also
affects the retrocyclization pathway. The tandem mass
spectrum of 17-DHES also showed fragment ions such
as m/z 171 which were consistent with retrocyclization
mode 2 and a retro-Diels-Alder reaction pathway in-
stead of mode 3. The -H rearrangement probably
occurred first followed by the retro-Diels-Alder reac-
tion. Signals at m/z 171 and 169 (loss of H2 from m/z 171)
were observed in low abundance in other tandem mass
spectra. These unique MS-MS fragmentation pathways
distinguished 17-DHES from 17-EQ as well as DHES
from EQ, which are two pairs of isomers differing only
by the position of a carbon-carbon double bond.
Eliminations of CH4 and COwere more favorable for
the ketone compounds than their hydroxyl derivatives.
For example, abundant ions ofm/z 249 andm/z 221 were
detected in the tandem mass spectrum of EN corre-
Scheme 5. Proposed fragmentation pathways of the deproto-
nated molecule of EN.sponding to [M  H  CH4]
 and [M  H  CH4-
278 SUN ET AL. J Am Soc Mass Spectrom 2005, 16, 271–279CO], respectively (Figure 4b). Fragmentation path-
ways for the formation of the ions of 249 and 221 are
shown in Scheme 5. The formation of the 13,14-double
bond during elimination of CH4 would be stabilized by
conjugation with the carbonyl group in these ketones.
In addition, the 13,14-double bond would be conjugated
with the double bond in the B-ring. The loss of CO from
the ketones was more favorable than from their hy-
droxyl derivatives, since fewer bonds would need to be
formed and broken. Although ions formed by elimina-
tions of CH4 and CO were more abundant in the ketone
estrogens (Figure 4b, d, f) than in the 17-hydroxyl
derivatives, the retrocyclization fragmentation modes
were still observed including retrocyclization mode 1
for EQ and DHES, mode 2 (retro-Diels-Alder fragmen-
tation) for DHES, mode 3 for EQ and EN, and mode 4
for EQ, EN and DHES.
Conclusions
We have developed a method using ultrafiltration and
LC-MS-MS to determine the relative affinities of human
and equine estrogens to human ER- and ER-. The
application of this method indicates that estrogens
containing a 17-OH moiety have higher affinities for
the estrogen receptors than their ketone analogs and
that 17-EN and EN bind selectively to ER- over ER-.
These findings are consistent with the values obtained
using a conventional radiolabled estradiol competitive
binding assay.
During the development of this ultrafiltration LC-
MS-MS assay, we investigated the tandem mass spectra
of these compounds in order to select suitable fragment
ions for MRM. Although either negative or positive ion
electrospray ionization produces abundant deproto-
nated or protonated molecules, respectively, we found
that only the deprotonated molecules produced unique
as well as abundant fragment ions of the isomeric
estrogens. Therefore, we used negative ion electrospray
ionization combined with CID and MRM during LC-
MS-MS for the unique identification and measurement
of the estrogens in the ultrafiltrates. While developing
this assay and interpreting the tandemmass spectra, we
identified and report here various retrocyclization path-
ways for these estrogens. These fragmentation path-
ways and various unique fragment ions may be used to
distinguish the estrogen isomers unambiguously and
should be useful during other investigations of these
compounds.
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